Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,an
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgenerat
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionve
systemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbee
studiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompa
toconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristic
recombinantproteins,uniquepost-translationalprocessingoftherHAininsectcellsinstillsfavourabletertiaryandquaternary
structuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexp
certainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotec
antibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsenc
eggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadv
reactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityof
recombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarg
suchasforCOVID-19.